Amgen/Daiichi Sankyo sign denosumab deal
California, USA-based biotechnology major Amgen and Japan's Daiichi Sankyo have entered into a licensing agreement for the former's monoclonal antibody therapeutic denosumab. The deal covers development and commercialization of the drug in Japan for proposed indications including post-menopausal osteoporosis and oncology.
Under the terms of the deal, Amgen has granted Daiichi Sankyo exclusive rights to the drug in Japan in return for a $20.0 million upfront payment. In addition, the Japanese firm, which will fund subsequent development of the drug in its home territory, will pay a further $150.0 million towards worldwide R&D costs as well as sales royalties.
In return, Daiichi is eligible to receive milestone payments contingent on the approval of the drug in both Japan and the European Union.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze